My Application Form Status

Check the status of your application form with Angel Broking.
Vivimed Labs intimate of successful USFDA inspection of FDF facility in Alathur
Nov 30,2016

Vivimed Labs announced that its FDF manufacturing facility located in Alathur, near Chennai has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection. The audit was conducted during the last week of November and concluded on 28 November 2016.

Furthermore, Vivimed obtained ANDA approval for Metronidazole and same is commercialised. During November 2016, the Company acquired ANDA of Zolpidem and the file transfer has successfully been completed. lt is expected to be commercialised by Q4 FY2O17. Vivimed is on trackof its filing targets and has successfully completed 3 ANDA filings during FY2017 and expect one more filing to be completed by Q4 FY2017. These products provide vertical integration with the inhouse APls.

Powered by Capital Market - Live News

Interactive Financial Services announces change in registered office
Nov 30,2016

Interactive Financial Services announced that the registered office of the Company has been changed to A-1006, Premium house, B/h Handloom house, Ashram Road, Ahmedabad - 380009.

Tel No: 91-79-26582851
Fax No: 91-79-26582328

Powered by Capital Market - Live News

Board of Centum Electronics approves proposal for further investment in Adetel Group SA
Nov 30,2016

Centum Electronics announced that the Board of Directors of the Company at its meeting held on 29 November 2016 approved the proposal for further investment in Adetel Group SA. With the proposed investment, Centum Electronics stake in Adetel Group will increase from 51% to 54%. Further, the above investment will be done through the wholly owned subsidiary company, Centum Electronics UK.

Powered by Capital Market - Live News

Eros International advances on fund raising plans
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the BSE Sensex was up 115.17 points, or 0.44%, to 26,509.66.

On the BSE, 7,267 shares were traded so far in the counter, compared with average daily volume of 43,372 shares in the past one quarter. The stock had hit a high of Rs 174.90 and a low of Rs 170.10 so far during the day. The stock had hit a 52-week high of Rs 274 on 4 December 2015. The stock had hit a 52-week low of Rs 125.90 on 29 February 2016. The stock had underperformed the market over the past one month till 29 November 2016, falling 12.25% compared with 5.54% fall in the Sensex. The scrip had also underperformed the market in past one quarter, falling 21.39% as against Sensexs 5.41% decline.

The small-cap company has equity capital of Rs 93.71 crore. Face value per share is Rs 10.

Eros International Media said that the meeting of board of directors of the company will be held on 2 December 2016, to consider and approve the proposal to raise funds through issue and offer of secured/unsecured, redeemable, non convertible debentures on public/private placement basis, in one or more tranches, upto the limit as may be decided by the board.

On a consolidated basis, net profit of Eros International Media fell 32.9% to Rs 62.99 crore on 5.2% decline in net sales to Rs 478.79 crore in Q2 September 2016 over Q2 September 2015.

Eros International Media operates in the Indian film entertainment industry. It acquires, co-produces and distributes Indian films across all available formats such as cinema, television and digital new media.

Powered by Capital Market - Live News

Lupin gets final approval for Generic Nuvigiln++ Tablets
Nov 30,2016

Lupin announced that its subsidiary, Lupin Pharmaceuticals Inc. has received final approval for its Armodafinil Tablets 50 mg, 150 mg, 200 mg and 250 mg from the United States Food and Drug Administration to market a generic version of Cephalon Incs Nuvigil Tablets mg, 150 mg, 200 mg and 250 mg. Lupin Pharmaceutical shall commence promoting the product in the US shortly.

Powered by Capital Market - Live News

HCC nudges higher on mulling preferential share allotment
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the S&P BSE Sensex was up 131.10 points or 0.5% at 26,525.11.

On the BSE, 3.95 lakh shares were traded on the counter so far as against the average daily volumes of 28.59 lakh shares in the past one quarter. The stock had hit a high of Rs 34.70 and a low of Rs 34.25 so far during the day. The stock had hit a 52-week high of Rs 41.90 on 14 September 2016. The stock had hit a 52-week low of Rs 16.60 on 12 February 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 7.02% compared with the Sensexs 5.54% fall. The scrip had, however, outperformed the market in past one quarter, surging 46.96% as against the Sensexs 5.41% fall.

The small-cap company has equity capital of Rs 77.92 crore. Face value per share is Rs 1.

Hindustan Construction Companys (HCC) board at its proposed board meeting on 2 December 2016, would consider issue of equity shares representing 24.44% of the expanded capital and also optionally convertible debentures (OCDs) on preferential basis, to be allotted collectively to the individual lenders. In this context, the company plans to convene an extraordinary general meeting (EGM) for seeking shareholders approval.

HCCs net profit fell 42.8% to Rs 23.08 crore on 8.2% decline in net sales to Rs 759.03 crore in Q2 September 2016 over Q2 September 2015.

HCC is into infrastructure development in transportation, power and water segments.

Powered by Capital Market - Live News

Gillette India appoints company secretary and compliance officer
Nov 30,2016

Gillette India announced that Flavia Machado has been appointed as Company Secretary & Compliance Officer of the Company effective 30 November 2016.

Powered by Capital Market - Live News

Board of India Home Loans to consider preferential issue of shares
Nov 30,2016

India Home Loans announced that a Board meeting has been scheduled on 2 December 2016 to consider the preferential issue and allotment of 29,11,755 equity shares of the Company to following investors - JM Financial Products, Chetan R Shah (HUF), Shailaja C Shah and Sonal M Shah.

Powered by Capital Market - Live News

Board of Ovobel Foods appoints company secretary
Nov 30,2016

Ovobel Foods announced that the Board of Directors of the Company at its meeting held on 29 November 2016 has approved the appointment of Ritu Singh as Company Secretary and Compliance Officer with effect from 29 November 2016.

Powered by Capital Market - Live News

GIC Estimates Size Of Non-Life Insurance Growing Five Times By 2026, Says Its Secretary General
Nov 30,2016

Secretary General, General Insurance Council, Mr. R Chandrasekaran forecast the size of non-life and liability insurance would grow five times by next decade as non-life and liability insurance is gradually growing a risk mitigation exercise in India.

Inaugurating a Seminar on Financial Risks & Liability Insurance : Current Scenario and Way forward organized by the PHD Chamber of Commerce and Industry, Mr. Chandrasekaran emphasized that with proper policy, ongoing innovations and regulations in place, the non-life and liability insurance which is currently estimated at a size of 3%, however, will stay put at this number for another 4-5 years and subsequently frogleap.

According to him, a great deal of public exercise and campaigning is called for to arise public awakening for larger participation of stakeholders in this non-life segment to enable it realize its latent potential.

Supportive regulations and policies are also needed for the growth of non-life insurance which would come about as this is what has happened for life insurance to pick up in India in the past, indicated Mr. Chandrasekaran and also urged the PHD Chamber to carry such conferences across other Tier-1 and Tier-2 cities of India.

In his opening remarks, Vice President, PHD Chamber, Mr. Anil Khaitan also hoped that with changing India, its liability and non-life insurance will also grow faster than anticipated as the Chamber is confident of its estimated growth and diversification.

Speaking on the occasion, Chairman, Insurance Committee of the Chamber, Mr. Yogesh Lohiya also exuded confidence saying that with skilling, digital and Make in India picking required pace, the non-life insurance sector is poised for higher growth. What is required is a massive campaign to promote this branch of insurance.

Managing Director, Nilam Sharma, Ms. Nilam Sharma in her presentation detailed out her perception on Directors and Officers relating to non-life insurance and their role to diversify and expand this sector.

Powered by Capital Market - Live News

Sarda Energy & Minerals spurts after restarting mining operations
Nov 30,2016

The announcement was made after trading hours yesterday, 30 November 2016.

Meanwhile, the BSE Sensex was up 92.11 points, or 0.35%, to 26,486.12.

On BSE, so far 59,000 shares were traded in the counter, compared with average daily volume of 86,198 shares in the past one quarter. The stock hit a high of Rs 256.65 and a low of Rs 235.50 so far during the day. The stock hit a 52-week high of Rs 296.60 on 1 November 2016. The stock hit a 52-week low of Rs 75.50 on 26 February 2016. The stock had underperformed the market over the past 30 days till 29 November 2016, falling 15.83% compared with the 5.50% decline in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 33.55% as against Sensexs 7.23% decline.

The small-cap company has equity capital of Rs 36.02 crore. Face value per share is Rs 10.

On 9 March 2016, Sarda Energy & Minerals announced temporary suspension of operation at its iron ore mine in Dongarbore (Chhattisgarh) after a naxalite attack on 7 March 2016, which caused death of one employee and damage of a few vehicles.

Net profit of Sarda Energy & Minerals rose 250.3% to Rs 12.54 crore on 2.7% decline in net sales to Rs 253 crore in Q2 September 2016 over Q2 September 2015.

Sarda Energy & Minerals (SEML) is one of the lowest cost producers of steel (sponge iron, billets, ingots, TMT bars) and one of the largest manufacturers and exporters of ferro alloys in India.

Powered by Capital Market - Live News

Vivimed Labs spurts after unit successfully completes USFDA inspection
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the S&P BSE Sensex was up 78.36 points or 0.3% at 26,472.37.

On the BSE, 3.78 lakh shares were traded on the counter so far as against the average daily volumes of 2.89 lakh shares in the past one quarter. The stock had hit a high of Rs 107.40 and a low of Rs 102 so far during the day. The stock had hit a record high of Rs 121.15 on 4 October 2016. The stock had hit a 52-week low of Rs 68 on 9 August 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 13.97% compared with the Sensexs 5.54% fall. The scrip had, however, outperformed the market in past one quarter, advancing 24.63% as against the Sensexs 5.41% fall.

The large-cap company has equity capital of Rs 16.20 crore. Face value per share is Rs 2.

The audit was conducted during the last week of November and concluded on 28 November 2016. Furthermore, Vivimed obtained abbreviated new drug application (ANDA) approval for Metronidazole and same is commercialised. During November 2016, the company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialised by Q4 March 2017.

Vivimed is on track of its filing targets and has successfully completed 3 ANDA filings during the current financial year and expect one more filing to be completed by Q4 March 2017. These products provide vertical integration with the in-house active pharmaceutical ingredients (APIs).

Santosh Varalwar, Managing Director of Vivimed Labs, said the company is on track with its filings pipeline which are expected to bear fruits when these products start to commercialise over the next 18-24 months.

On a consolidated basis, Vivimed Labs net profit rose 12.4% to Rs 26.85 crore on 11.5% decline in net sales to Rs 298.36 crore in Q2 September 2016 over Q2 September 2015.

Vivimed Labs is a niche specialty chemicals and pharmaceuticals company.

Powered by Capital Market - Live News

Lupin gains after receiving USFDA approval for Armodafinil tablets
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the BSE Sensex was up 67.23 points, or 0.25%, to 26,461.24.

On BSE, so far 25,000 shares were traded in the counter, compared with average daily volume of 99,927 shares in the past one quarter. The stock hit a high of Rs 1,545.55 and a low of Rs 1,526.90 so far during the day. The stock hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had outperformed the market over the past 30 days till 29 November 2016, falling 0.06% compared with the 5.50% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 2.25% as against Sensexs 7.23% decline.

The large-cap company has equity capital of Rs 90.27 crore. Face value per share is Rs 2.

Lupin announced that its US subsidiary Lupin Pharmaceuticals Inc (LPI) has received final approval from the United States Food and Drug Administration (USFDA) to market Armodafinil tablets 50mg, 150mg, 200mg and 250mg. LPI shall commence promoting the product in the US shortly. Lupins Armodafinil tablets are the AB rated generic equivalents of Cephalon, Incs Nuvigil tablets. Armodafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy or shift work disorder (SWD). Nuvigil tablets had annual US sales of $515.6 million as per IMS MAT September 2016 data.

Lupins consolidated net profit jumped 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Powered by Capital Market - Live News

Tamil Nadu Newsprint & Papers standalone net profit rises 18.56% in the September 2016 quarter
Nov 30,2016

Net profit of Tamil Nadu Newsprint & Papers rose 18.56% to Rs 70.58 crore in the quarter ended September 2016 as against Rs 59.53 crore during the previous quarter ended September 2015. Sales rose 22.48% to Rs 667.05 crore in the quarter ended September 2016 as against Rs 544.63 crore during the previous quarter ended September 2015.

ParticularsQuarter Endedn++Sep. 2016Sep. 2015% Var. Sales667.05544.63 22 OPM %26.4525.34 - PBDT132.38110.90 19 PBT79.5176.42 4 NP70.5859.53 19

Powered by Capital Market - Live News

Wanbury reports standalone net profit of Rs 7.07 crore in the September 2016 quarter
Nov 30,2016

Net profit of Wanbury reported to Rs 7.07 crore in the quarter ended September 2016 as against net loss of Rs 2.44 crore during the previous quarter ended September 2015. Sales rose 14.43% to Rs 120.86 crore in the quarter ended September 2016 as against Rs 105.62 crore during the previous quarter ended September 2015.

ParticularsQuarter Endedn++Sep. 2016Sep. 2015% Var. Sales120.86105.62 14 OPM %10.018.91 - PBDT9.45-0.21 LP PBT7.07-2.44 LP NP7.07-2.44 LP

Powered by Capital Market - Live News